Presented in part at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17–22, 2003. Received Jan. 29, 2004; revision received June 13, 2004; accepted July 8, 2004. From the Department of Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, N.Y.; and Albert Einstein College of Medicine, Bronx, N.Y. Address correspondence and reprint requests to Dr. Straker, Columbia University Medical Center, Presbyterian Hospital, 622 West 168th St., PH-16, New York, NY 10032; firstname.lastname@example.org (e-mail). Supported by The Zucker Hillside Hospital Intervention Research, Center for Schizophrenia; by NIMH grant 5P30 MH-60575; and by Stanley Research Fellowship grant 3924 (medical students Koshy and Saint-Vil). Christoph U. Correll, M.D., is on the Speaker’s Bureau of AstraZeneca, Janssen Pharmaceutica, and Bristol-Myers Squibb. John M. Kane, M.D., is a consultant to Pfizer, Janssen Pharmaceutica, Abbott, Lilly, and Bristol-Myers Squibb.